Juvela Seppo, Siironen Jari, Lappalainen Jaakko
Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Turku, Finland.
J Neurosurg. 2009 May;110(5):989-95. doi: 10.3171/2008.11.JNS081266.
After aneurysmal subarachnoid hemorrhage (SAH), conflicting results concerning an association between the APOE genotype and impaired outcome have been reported. The authors tested prospectively whether APOE epsilon2 or epsilon4 allele-containing genotypes (epsilon2+ and epsilon4+) affect outcome after SAH.
Previous disease histories and clinical and radiological variables were recorded for 105 patients who were admitted within 48 hours after SAH. Fifteen patients (14%) had the epsilon2+ genotype and 31 (30%) [corrected] had epsilon4+ genotypes. Factors predicting poor outcome according to the Glasgow Outcome Scale and cerebral infarction visible on CT scans obtained at 3 months after SAH were tested with multiple logistic regression analyses.
Apolipoprotein E epsilon2 or epsilon4-containing genotypes were not associated with outcome, occurrence of cerebral infarction, or with any of their predictors, either in univariate or multivariate analysis. Poor outcome was predicted independently by the occurrence of intraventricular bleeding and intracerebral hematoma as well as by elevated levels of both plasma glucose and D-dimer, and delayed cerebral ischemia (p < 0.05 for each factor), and in univariate analysis only by clinical condition on admission and patient age. Cerebral infarction was predicted independently according to clinical condition on admission (p < 0.05), amount of subarachnoid blood (p < 0.01), duration of intraoperative parent artery clipping (p < 0.01), and body mass index (p < 0.05). In the univariate analysis only cerebral infarction was also predicted by patient age, intracerebral hematoma, and delayed cerebral ischemia.
Severity of bleeding for the most part predicts outcome after SAH; APOE polymorphisms seem to have no prognostic value for outcome after SAH. This result was in accordance with the findings from the largest ischemic stroke studies.
关于动脉瘤性蛛网膜下腔出血(SAH)后,载脂蛋白E(APOE)基因与不良预后之间的关联,已有相互矛盾的研究结果报道。作者前瞻性地测试了含APOEε2或ε4等位基因的基因型(ε2+和ε4+)是否会影响SAH后的预后。
记录了105例在SAH后48小时内入院患者的既往病史、临床及影像学变量。15例患者(14%)为ε2+基因型,31例(30%)[校正后]为ε4+基因型。通过多因素logistic回归分析,对根据格拉斯哥预后量表和SAH后3个月CT扫描显示的脑梗死来预测不良预后的因素进行了测试。
在单因素或多因素分析中,含载脂蛋白Eε2或ε4的基因型与预后、脑梗死的发生或其任何预测因素均无关联。独立预测不良预后的因素为脑室内出血和脑内血肿的发生、血浆葡萄糖和D - 二聚体水平升高以及迟发性脑缺血(各因素p < 0.05),在单因素分析中,仅入院时的临床状况和患者年龄可预测不良预后。独立预测脑梗死的因素为入院时的临床状况(p < 0.05)、蛛网膜下腔出血量(p < 0.01)、术中母动脉夹闭时间(p < 0.01)和体重指数(p < 0.05)。在单因素分析中,仅脑梗死还可由患者年龄、脑内血肿和迟发性脑缺血预测。
出血的严重程度在很大程度上可预测SAH后的预后;APOE基因多态性似乎对SAH后的预后无预后价值。这一结果与最大规模缺血性卒中研究的结果一致。